DDInter119 DDInter1701
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Sonidegib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Sonidegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Sonidegib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Sonidegib {u} may lead to a major life threatening interaction when taken with {v} Duvelisib
Sonidegib {u} may lead to a major life threatening interaction when taken with {v} Nafcillin
Sonidegib may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Sonidegib may lead to a major life threatening interaction when taken with Duvelisib
Sonidegib may lead to a major life threatening interaction when taken with Nafcillin